JP2005520523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005520523A5 JP2005520523A5 JP2003577595A JP2003577595A JP2005520523A5 JP 2005520523 A5 JP2005520523 A5 JP 2005520523A5 JP 2003577595 A JP2003577595 A JP 2003577595A JP 2003577595 A JP2003577595 A JP 2003577595A JP 2005520523 A5 JP2005520523 A5 JP 2005520523A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- antigen
- binding portion
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000056 organ Anatomy 0.000 claims description 5
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000008383 multiple organ dysfunction Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36705402P | 2002-03-21 | 2002-03-21 | |
| US40976802P | 2002-09-10 | 2002-09-10 | |
| PCT/US2003/006155 WO2003079750A2 (en) | 2002-03-21 | 2003-03-12 | ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005520523A JP2005520523A (ja) | 2005-07-14 |
| JP2005520523A5 true JP2005520523A5 (https=) | 2006-04-20 |
Family
ID=28457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577595A Pending JP2005520523A (ja) | 2002-03-21 | 2003-03-12 | アンタゴニスト的抗ｈＦａｓリガントヒト抗体およびそのフラグメント |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7262277B2 (https=) |
| EP (1) | EP1490405B1 (https=) |
| JP (1) | JP2005520523A (https=) |
| CN (1) | CN1283662C (https=) |
| AT (1) | ATE370970T1 (https=) |
| AU (1) | AU2003219954B2 (https=) |
| BR (1) | BR0308401A (https=) |
| CA (1) | CA2478386A1 (https=) |
| DE (1) | DE60315815T2 (https=) |
| DK (1) | DK1490405T3 (https=) |
| ES (1) | ES2291626T3 (https=) |
| IL (1) | IL164011A0 (https=) |
| MX (1) | MXPA04009148A (https=) |
| PT (1) | PT1490405E (https=) |
| WO (1) | WO2003079750A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| LT2857418T (lt) | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
| CA2619298C (en) * | 2005-08-26 | 2017-07-04 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
| EP2231708B1 (en) * | 2007-12-12 | 2015-04-08 | Pincell Srl | Remedies for pemphigus containing anti-fas ligand antibodies |
| US20110189194A1 (en) * | 2008-07-14 | 2011-08-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| JP5773882B2 (ja) | 2008-12-12 | 2015-09-02 | ピンチェル ソチエタ・レスポンサビリタ・リミタータＰｉｎＣｅｌｌ ｓｒｌ | 抗ＦａｓＬリガンド抗体を含有する天疱瘡用治療薬 |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| JP2016508606A (ja) * | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
| JP6556121B2 (ja) * | 2013-04-29 | 2019-08-07 | アポジェニックス アーゲー | 癌を診断する方法 |
| WO2015165973A1 (en) | 2014-04-29 | 2015-11-05 | Apogenix Gmbh | Diagnostic anti-cd95l antibody |
| US20220289827A1 (en) * | 2021-03-11 | 2022-09-15 | Washington University | Neutralizing antibodies to sars-cov-2 and its variants |
| CN116888257A (zh) * | 2022-01-21 | 2023-10-13 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2023138522A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| US20250257141A1 (en) | 2022-04-26 | 2025-08-14 | Hoffmann-La Roche Inc. | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
| WO2024200287A1 (en) | 2023-03-24 | 2024-10-03 | Pincell S.R.L. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
| EP4474395A1 (en) | 2023-06-06 | 2024-12-11 | PinCell S.r.l. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
| WO2025196289A1 (en) | 2024-03-22 | 2025-09-25 | Pincell S.R.L. | New target affinity and specificity of anti sfas-l antibody, pc111 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| JPH09508009A (ja) | 1994-01-07 | 1997-08-19 | イミュネックス・コーポレーション | Ｆａｓ抗原を結合するリガンド |
| US6096312A (en) | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| CA2225852C (en) * | 1995-06-30 | 2009-04-14 | Mochida Pharmaceutical Co., Ltd. | Anti-fas ligand antibody and assay method using the anti-fas ligand antibody |
| US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
-
2003
- 2003-03-12 WO PCT/US2003/006155 patent/WO2003079750A2/en not_active Ceased
- 2003-03-12 ES ES03716239T patent/ES2291626T3/es not_active Expired - Lifetime
- 2003-03-12 DK DK03716239T patent/DK1490405T3/da active
- 2003-03-12 AU AU2003219954A patent/AU2003219954B2/en not_active Ceased
- 2003-03-12 US US10/506,743 patent/US7262277B2/en not_active Expired - Fee Related
- 2003-03-12 PT PT03716239T patent/PT1490405E/pt unknown
- 2003-03-12 BR BR0308401-9A patent/BR0308401A/pt not_active IP Right Cessation
- 2003-03-12 MX MXPA04009148A patent/MXPA04009148A/es active IP Right Grant
- 2003-03-12 AT AT03716239T patent/ATE370970T1/de not_active IP Right Cessation
- 2003-03-12 EP EP03716239A patent/EP1490405B1/en not_active Expired - Lifetime
- 2003-03-12 CA CA002478386A patent/CA2478386A1/en not_active Abandoned
- 2003-03-12 DE DE60315815T patent/DE60315815T2/de not_active Expired - Lifetime
- 2003-03-12 CN CNB038064030A patent/CN1283662C/zh not_active Expired - Fee Related
- 2003-03-12 JP JP2003577595A patent/JP2005520523A/ja active Pending
- 2003-03-12 IL IL16401103A patent/IL164011A0/xx unknown